These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Fang W; Oreopoulos DG; Bargman JM Nephrol Dial Transplant; 2008 Nov; 23(11):3704-10. PubMed ID: 18567695 [TBL] [Abstract][Full Text] [Related]
3. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis. Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644 [TBL] [Abstract][Full Text] [Related]
4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
5. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912 [TBL] [Abstract][Full Text] [Related]
6. [Risk and prevention of diabetic nephropathy]. Ravera M; Re M; Deferrari G G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442 [TBL] [Abstract][Full Text] [Related]
7. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Ferrari P Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Hughes DB; Britton ML Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022 [TBL] [Abstract][Full Text] [Related]
9. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552 [TBL] [Abstract][Full Text] [Related]
10. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536 [TBL] [Abstract][Full Text] [Related]
11. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure. Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H; Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311 [TBL] [Abstract][Full Text] [Related]
13. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574 [TBL] [Abstract][Full Text] [Related]
14. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. Krairittichai U; Chaisuvannarat V J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520 [TBL] [Abstract][Full Text] [Related]
15. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II). Jacobsen PK J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484 [TBL] [Abstract][Full Text] [Related]
16. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748 [TBL] [Abstract][Full Text] [Related]
17. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Richter B; Derntl M; Marx M; Lercher P; Gössinger HD Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648 [TBL] [Abstract][Full Text] [Related]
18. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Pathak JV; Dass EE Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372 [TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness of angiotensin receptor blockers in patients with type 2 diabetes mellitus and nephropathy in Israel]. Berar-Yanay N; Leshno M; Hertzeanu L; Weintrob N Harefuah; 2008 Mar; 147(3):211-5, 278. PubMed ID: 18488861 [TBL] [Abstract][Full Text] [Related]
20. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus]. Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]